1312608-46-0
1312608-46-0 structure
- Name: Coblopasvir
- Chemical Name: Methyl {(2S)-1-[(2S)-2-{5-[7-(4-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-pyrrolidinyl]-1H-imidazol-5-yl}phenyl)-1,3-benzodioxol-4-yl]-1H-imidazol-2-yl}-1-pyrrolidinyl]-3-methyl-1-oxo-2-butanyl}carbamate
- CAS Number: 1312608-46-0
- Molecular Formula: C41H50N8O8
- Molecular Weight: 782.885
- Catalog: Signaling Pathways Anti-infection HCV
- Create Date: 2020-01-12 14:01:50
- Modify Date: 2025-09-19 15:32:34
-
Coblopasvir (KW136, KW-136) is a novel HCV NS5A inhibitor under development for treatment of HCV infection. HCV Infection Phase 3 Clinical
| Name | Methyl {(2S)-1-[(2S)-2-{5-[7-(4-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-pyrrolidinyl]-1H-imidazol-5-yl}phenyl)-1,3-benzodioxol-4-yl]-1H-imidazol-2-yl}-1-pyrrolidinyl]-3-methyl-1-oxo-2-butanyl}carbamate |
|---|---|
| Synonyms |
Methyl {(2S)-1-[(2S)-2-{5-[7-(4-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-pyrrolidinyl]-1H-imidazol-5-yl}phenyl)-1,3-benzodioxol-4-yl]-1H-imidazol-2-yl}-1-pyrrolidinyl]-3-methyl-1-oxo-2-butanyl}carbamate
Carbamic acid, N-[(1S)-1-[[(2S)-2-[5-[4-[7-[2-[(2S)-1-[(2S)-2-[(methoxycarbonyl)amino]-3-methyl-1-oxobutyl]-2-pyrrolidinyl]-1H-imidazol-5-yl]-1,3-benzodioxol-4-yl]phenyl]-1H-imidazol-2-yl]-1-pyrrolidinyl]carbonyl]-2-methylpropyl]-, methyl ester |
| Description | Coblopasvir (KW136, KW-136) is a novel HCV NS5A inhibitor under development for treatment of HCV infection. HCV Infection Phase 3 Clinical |
|---|---|
| References | References View Related Products by Target HCV HCV Infection |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 1102.5±65.0 °C at 760 mmHg |
| Molecular Formula | C41H50N8O8 |
| Molecular Weight | 782.885 |
| Flash Point | 620.6±34.3 °C |
| Exact Mass | 782.375183 |
| LogP | 5.30 |
| Vapour Pressure | 0.0±0.3 mmHg at 25°C |
| Index of Refraction | 1.603 |
| Storage condition | -20°C |
| Hazard Codes | Xn |
|---|